Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (19360)	4/22/1998 7:20:00 PM
From: WTDEC	Respond to of 32384

" Ligand is not specifically mention in the WSJ article (although Ligand was mentioned in the initial WSJ article on designer estrogens, aka SERMs or TSEs home.att.net but its programs certainly are (with PFE and AHP). The article hasn't quite progressed to combination therapy (with SERMs and Rexinoids which is the subject of one of the LLY programs with LGND), but it does mention prostate cancer and LGND's pipeline timeline (linked to home.att.net or accessed directly at home.att.net ) clearly shows that LGND's designer androgen, LGD1331, is ready to enter the clinic" H, based on my research, this area may well prove to be LGND's greatest strength. LGND seems to be way ahead of any competition here and has partners who will help with the heavy lifting necessary to get products to the market. Regards, W

To: Henry Niman who wrote (19360)	4/22/1998 7:25:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 32384

"CNBC just mentioned Evista and braest cancer prevention and, as ASCO approaches (conference is next month), I expect such an application to be discussed with increasing frequency in the popular press (Evista produced a 75% reduction in the incidence of breast cancer compared to the 45% seen for Tamoxifen)." H, the Evista numbers are better than the Targretin rat data which I recall. However, I also seem to recall there is an expectation for synergy? How foggy is my memory here? Regards, W